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Development of a Bayesian
response-adaptive trial design
for the Dexamethasone for
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Abstract
It is often unclear what specific adaptive trial design features lead to an efficient design which is also
feasible to implement. This article describes the preparatory simulation study for a Bayesian response-
adaptive dose-finding trial design. Dexamethasone for Excessive Menstruation aims to assess the efficacy
of Dexamethasone in reducing excessive menstrual bleeding and to determine the best dose for further
study. To maximise learning about the dose response, patients receive placebo or an active dose with
randomisation probabilities adapting based on evidence from patients already recruited. The dose-
response relationship is estimated using a flexible Bayesian Normal Dynamic Linear Model. Several
competing design options were considered including: number of doses, proportion assigned to placebo,
adaptation criterion, and number and timing of adaptations. We performed a fractional factorial study
using SAS software to simulate virtual trial data for candidate adaptive designs under a variety of scenarios
and to invoke WinBUGS for Bayesian model estimation. We analysed the simulated trial results using
Normal linear models to estimate the effects of each design feature on empirical type I error and
statistical power. Our readily-implemented approach using widely available statistical software identified
a final design which performed robustly across a range of potential trial scenarios.
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1 Introduction
Adaptive designs generally oﬀer added ﬂexibility and eﬃciency over conventional trial designs.
However, it is diﬃcult to select the design options that provide an eﬀective adaptive design which
is also feasible to implement. Before deciding on a particular design, it is generally advisable to carry
out a simulation study.
The methodology of Bayesian adaptive designs has grown steadily in recent years; alongside this,
publications providing guidance on simulation studies for the development of Bayesian response-
adaptive designs1 are a valuable resource. Characterising the properties of competing adaptive
designs and choosing a ‘best design’ to take forward is not a trivial task. In this paper, we
describe our experiences from a simulation study which was conducted to develop the response-
adaptive dose-ﬁnding study design for the MRC-funded Dexamethasone for Excessive
Menstruation trial (DexFEM; MRC reference: MR/J003611/1).
2 Outline
A brief account of the background and motivation for the DexFEM study is provided in section 3
along with a description of the methods planned for the analysis of this adaptive trial. The design
development study is introduced in section 4 which gives an account of the design options and
scenarios that are investigated in the trial simulations. Sections 5 and 6 give details of the simulation
engine and the methods used to summarise the simulated trial results. The ﬁndings from the design
development study are presented in section 7. Section 8 explains the subsequent choice of the
adaptive design for DexFEM followed by more general discussion of our approach in a wider
context in section 9.
3 The DexFEM study
Heavy Menstrual Bleeding (HMB) is a common problem, yet existing medical treatments are often
ineﬀective. Surgical treatments such as hysterectomy, are unacceptable to many, particularly those
who wish to preserve their fertility. DexFEM aims to establish if Dexamethasone (a synthetic
glucocorticoid) taken orally is eﬀective in reducing menstrual blood loss (MBL) in women with
heavy menstrual bleeding.
Women with HMB may have glucocorticoid deﬁciency in the lining of the womb (endometrium)
and as a consequence impaired blood vessel function and increased menstrual blood loss.2 We
propose ‘‘rescue’’ of such a deﬁciency could reduce excessive menstrual bleeding. The published
DexFEM protocol provides further details of the trial.3
The optimal dose for achieving eﬃcacy and few adverse eﬀects is unknown but is likely to be
between 0.4mg and 1.8mg per day. The aims of the DexFEM trial are: (1) to establish whether
Dexamethasone in this dose range is eﬃcacious in reducing menstrual blood loss and (2) to identify
which is the best dose for further study in a later trial.
To estimate the dose-response curve we aim to enrol up to 108 women with HMB to achieve 100
completers in a response-adaptive, multi-arm, parallel-group dose-ﬁnding trial. Participants are
randomised to receive either placebo or one of several active doses in the range 0.4mg to 1.8mg.
Allocation probabilities are equal across the active doses at the start of recruitment but will be
updated for subsequent trial participants as outcome data begin to accrue and information is
gathered about the likely shape of the dose-response curve. This strategy has the advantage that
more information is obtained in the critical region of the underlying dose-response curve and fewer
women are randomised to less eﬀective doses. To limit potential bias in the randomised comparisons
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at the end of the study due to a drift in participant characteristics across time, the placebo allocation
rate will remain constant throughout the study. Thus, the allocation rate to placebo is the only one
that is not subject to adaptation.
Two characteristics of menstrual bleeding research are relevant to DexFEM. (1) Cycle. The
symptoms of HMB occur only cyclically according to the pattern of menstruation (most usually 5
to 8 days menstruation starting every 26 to 29 days, but variable even within women). In
DexFEM, we wish to trial three cycles of treatment. (2) Outcome. Following collection of
sanitary protection by the patient, laboratory estimation of menstrual blood loss volume for
the period can be achieved within a few days of the end of the period making it a suitable
outcome for use in an adaptive design. In DexFEM only the second and third treated cycles
involve menstrual blood volume measurement.
3.1 Modelling the dose-response
The dose-response curve is estimated using Bayesian methods in a second order Normal Dynamic
Linear Model4 (NDLM). Such models oﬀer ﬂexibility over non-dynamic models as few restrictions
are placed on the shape of the estimated curve. NDLMs also lead to eﬃciency gains since the
treatment eﬀect estimate at a given dose is also informed by that of neighbouring doses.
The NDLM is speciﬁed in terms of an observation equation and an evolution equation. Our
observation equation
Yi ¼ j þ Ybli þ i i ¼ 1, . . . , 100; j ¼ 1, . . . , J; i  i:i:d: Nð0, 2 Þ
models Yi, the MBL change from baseline to follow-up in subject i, as a linear function of the mean-
centred baseline MBL Ybli, and j, the treatment eﬀect at dose level j.  is the regression coeﬃcient
for Ybli and i is the observational error term.
The evolution equation
j ¼ j1 þ j1 þ !j
j ¼ j1 þ "j j ¼ 1, . . . , J;!j, "j  i:i:d: Nð0, 2!Þ
equates the treatment eﬀect at dose level j to the treatment eﬀect at the previous dose level plus a
systematic deviation, j 1, and an evolution error, !j. Finally j, the change in treatment eﬀect
from dose level j to dose level jþ 1, is essentially modelled as a random walk with step size
governed by N(j 1, !
2). The model formulation therefore assumes linear changes in the
treatment eﬀect from one dose level to the next but avoids restricting the overall curve to
follow a particular parametric speciﬁcation or even monotonicity (Figure 1). i, !j and "j are
mutually as well as internally independent. !j and "j are restricted to have the same variance to
limit the number of parameters needing estimated with this relatively small sample size. Similarly,
the observation and evolution error variances are assumed constant for all subjects and dose
levels.
We used the freely available WinBUGS software5 to estimate this system of equations using
Bayesian methods. We deﬁned the variance of the evolution error as a multiple of the
observational error variance such that !
2¼W2. A uniform U(0.001, 100) prior distribution
was speciﬁed for W and a vague half-normal prior distribution N(0, 100), deﬁned only on the
non-negative range of the scale, was placed on 
2. We also speciﬁed prior N(0, 10000)
distributions for 0, 0, and .
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3.2 Adaptation after interim analyses
A conventional design might randomise all trial participants evenly across the active dose range
before deriving, at the end, a ﬁnal model estimate of the dose-response curve. With our adaptive
design we will, while recruitment is still ongoing, apply the NDLM to the available outcome data
already accrued to obtain intermediate estimates of the dose-response curve. Evidence of emerging
trends can then inform adaptation of randomisation probabilities to the active doses for future
trial participants in a way that optimises estimation of the dose-response curve according to some
pre-deﬁned criterion. Typically as the trial progresses, more participants are randomised to doses
which are emerging as more eﬀective so that the dose-response curve in the range containing these
doses may be estimated with greater precision than would have been the case in a conventional
design.
The criterion on which adaptation is based might be a simple rule, for example to allocate future
participants using probabilities that are proportional to current eﬀect estimates at each dose level. It
might also be a more complex function of the predicted utility of future randomisations at each dose
level, for example using a measure of the precision with which the optimal dose level is estimated, or
alternatively, a measure of the precision with which eﬃcacy is estimated at the optimal dose level.
The criterion should reﬂect the trial objectives and is likely to diﬀer depending on whether the
primary interest is to obtain a robust estimate of the dose-response curve across the entire dose
Figure 1. Illustration of a Normal Dynamic Linear Model fit to simulated trial data based on a theoretical
dose–response relationship. The figure shows the theoretical dose-response curve, the piecewise linear fit derived
from the Normal Dynamic Linear Model and the actual observed means from a single simulated trial realisation
(stars).The outlying mean at 0.4mg was based on just six patients randomised to this dose and consequently had a
relatively smaller influence on the model estimate of the treatment effect at that dose.
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range or just around the optimum dose level. As our second aim is to identify the best dose for
further study, we applied a commonly used deﬁnition of the optimal dose: the ED95, the smallest
dose which achieves at least 95% of the maximum treatment eﬀect.
4 The design development study
We aimed to develop a feasible adaptive design: that is, one with a limited number of scheduled
adaptations and a speciﬁed number of possible doses (to allow the pharmacy to prepare capsules in
advance). A balance was therefore needed between satisfying these feasibility criteria and obtaining
eﬀective adaptation. To this end, we considered several diﬀerent designs and assessed the suitability
of each for DexFEM in a comprehensive pre-trial simulation study. The aim of the design
development study was to generate simulated trial results to characterise the properties of
candidate designs in terms of type I error and statistical power and ultimately to identify one
design which would perform well across a broad range of scenarios.
4.1 Design options
4.1.1 Dose levels
A daily Dexamethasone dose of 1.5mg was used in two small pilot trials, the dose being selected
based on experience with the drug in other indications and its planned use for 5-day treatment across
repeated menstrual cycles. No safety concerns emerged. The adaptive trial provides an opportunity
to estimate the dose-response curve over as wide a dose range as possible. Clinical judgment was that
1.8mg was the maximum dose that should be tested, so the daily dose levels selected for study were
0.4mg, 0.8mg, 1.0mg, 1.2mg, 1.5mg and 1.8mg.
It was not clear how many doses we could reliably study in the trial. Would a design with the
maximum practical number of doses perform better since intervals between observed points on the
dose-response curve are shorter, or would a design with fewer doses perform better since better
precision would be achieved in the treatment eﬀect estimates at each dose level? We investigated this
in the design development study (Table 1).
4.1.2 Number and spacing of adaptations
In principle, the ideal design would encompass model re-estimation and subsequent adaptation of
future allocation probabilities to each of the active doses with every new MBL measurement
collected. In practice, a fully sequential design of this sort would be unnecessarily challenging and
work-intensive and with little eﬃciency gain over a simpler design with fewer adaptations (based on
what we learned from initial exploratory simulation work). We assessed the performance of designs
with one, three and ﬁve adaptations over the course of recruitment as well as non-adaptive designs
(zero adaptations) for comparison. Within each design, adaptations were scheduled at pre-deﬁned
points during the recruitment phase. An example of a design with one adaptation [see Table 1,
section 1.2(b)] is a trial where the ﬁrst 50 participants are allocated with equal probability to any of
the dose levels (including placebo). An interim analysis is then carried out after the 50th participant
has been randomised, following which allocation probabilities for subsequent participants are
adapted to increase the potential for a successful trial outcome in light of the evidence collected
so far. In this example the adaptation was scheduled exactly half-way through the 100 planned
randomisations but would adaptations scheduled earlier or later in the recruitment phase perform
better, or should they instead be spaced evenly between randomisations throughout recruitment? We
assessed the performance of ten adaptation schedules [Table 1, section 1.2 (a)–(j)].
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Table 1. Design options and trial scenarios investigated in the design development study.
1. Design options
1.1 Active dose levels to include for investigation
(a) 0.4mg, 0.8mg, 1.0mg, 1.2mg, 1.5mg, 1.8mg
(b) 0.4mg, 1.0mg, 1.5mg, 1.8mg
1.2 Timing of adaptations (in terms of number of patients randomised)
(a) 33
(b) 50
(c) 66
(d) 10, 35 and 60
(e) 20, 45 and 70
(f) 49, 66 and 83
(g) 12, 24, 36, 48 and 60
(h) 16, 32, 50, 66 and 84
(i) 44, 55, 66, 77 and 88
(j) (no adaptation)
1.3 Placebo allocation rate (in design with J-1 active doses)
(a) 1/J
(b) 2/J
1.4 Criterion for adaptation (allocation probabilities are)
(a) scaled in proportion to probability that dose is efficacious (play-the-winner)
(b) based on predicted information gain resulting from a future randomisation at each dose
2. Scenarios
2.1 Variance of intra-participant MBL measurements
(a) se
2¼ (17.9mL)2
(b) se
2¼ (22.0mL)2
(c) se
2¼ (26.0mL)2 (only used when simulating heteroscedasticity)
2.2 Shape of dose-response curve
(a) Steep incline towards higher end of dose-range
(b) Slow incline with increasing dose levels
(c) Non-monotonic with maximum at 1.2mg
(d) Flat (i.e. no effect)
2.3 Magnitude of effect at maximum effective dose
(a) 8.2mL
(b) 16.4mL
2.4 Heteroscedasticity
(a) Absent
(b) Present
2.5 Mechanism of treatment
(a) Effect independent of baseline MBL
(b) Effect magnitude proportionate to baseline MBL
2.6 Enrolment rate
(a) 2 participants per month
(b) 4 participants per month
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4.1.3 Placebo allocation rate
The placebo allocation probability remained ﬁxed throughout the trial. For a design with J-1 active
doses we had initially planned to allocate participants to receive placebo with probability 1/J, such
that participants during the initial phase of recruitment, i.e. before the ﬁrst adaptation, would have
equal probability of being allocated to any of the J treatment arms. However, in order to cover the
range of values successfully implemented in previous multi-arm multi-stage adaptive trials6,7 we
assessed the performance of designs using placebo allocation probabilities of both 1/J and 2/J.
4.1.4 Criterion for adaptation of active dose randomisation probabilities
We evaluated two options for the choice of criterion for adaptation. One was the ‘play-the-winner’
rule where subsequent trial participants are randomly allocated to one of the active doses in
proportion to the posterior probability that the treatment dose eﬀects at least some reduction in
MBL as evaluated in the interim analysis.
The second adaptation criterion considered was a utility function which quantiﬁes the
information gain from future randomisations at each dose level. The function we used was the
predicted variance of the response at the current ED95 estimate after one future randomisation at
each of the active doses. Subsequent trial participants were then randomised in proportion to the
predicted increase in precision that would result from a randomisation at each dose.
To avoid computationally intensive nested MCMC routines, we used importance sampling8 as
applied by Weir et al.9 to predict the variance of the response at ED95 after one future
randomisation. At each dose, the predicted variance is based on M¼ 100 predictions for the
future observed MBL diﬀerence and for each of these we estimate the posterior predictive
distribution for the response at ED95 based on t¼ 10,000 iterations of the MCMC sampler.
4.1.5 Other considerations
The response variable, Y¼YfuYbl, was the diﬀerence between the baseline MBL measurements
obtained at screening, Ybl, and the follow-up MBL measurements, Yfu, collected during the
treatment phases of the trial. Early simulation results suggested that we were able to reduce the
variance of the modelled outcome, Var(YjYbl) by about 50% by collecting MBL measurements
over two menstrual cycles at screening, Y1 and Y2, and similarly over two cycles at follow-up, Y3 and
Y4, and letting Ybl¼ (Y1þY2)/2 and Yfu¼ (Y3þY4)/2. As these twin measurements at baseline
and follow-up had been planned from the outset, and in light of the resultant reduction in variance,
we decided not to reduce the number of menstrual cycles monitored during a woman’s trial
participation.
4.2 Scenarios
The above design options were assessed under a number of alternative assumptions for the true
dose-response curve and other unknown parameters to ensure that the ﬁnal design chosen would
perform well under a broad range of scenarios. The choice of scenarios to be assessed was informed
both by empirical data from previous studies and through careful elicitation of expert opinion from
the clinical team guided by the Sheﬃeld Elicitation Framework (SHELF10).
The variance of repeated intra-participant MBL measurements, e
2, was likely to have a large
eﬀect on the probability of a successful trial. Data from an observational study11 suggested normally
distributed within-participant errors with a variance of e
2¼ 17.9mL. We also investigated scenarios
with e
2¼ 22.0mL and e2¼ 26.0mL. There was also some evidence from this source of increasing
variance with greater MBL measurements. Design options were therefore investigated under both
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homo- and heteroscedastic errors. Heteroscedasticity was induced in the simulated within-
participant errors through a simple parametric function of the baseline MBL (Appendix 1) based
on empirical data.11
The likely mechanism of a treatment eﬀect on participants’ MBL was also considered. Treatment
eﬀects in medical research are often modelled as an absolute change independent of baseline levels of
the outcome variable. In practice, the health improvement which results from a medical treatment is
often dependent on the initial severity of the problem. Generally, treatment of a bigger problem
results in greater improvements in absolute terms. Our investigation of candidate designs was
therefore extended to include simulated scenarios where the treatment eﬀect was 10% or 20% of
the baseline MBL measurement at the most eﬀective dose, for small and large simulated treatment
eﬀect magnitudes respectively.
We did not incorporate the modelling of heteroscedasticity and interactions between treatment
eﬀects and baseline MBL levels in the NDLM, yet these were included as plausible scenarios
essentially to assess the robustness of the design for these scenarios where the model is misspeciﬁed.
We also included a number of scenarios for the shape of the true dose-response curve and the
magnitude of the treatment eﬀect at the maximum-eﬀective dose level (Figure 2). The trial enrolment
rate was also believed to be of importance since participants randomised during the follow-up phase
of other participants and during the time taken to carry out model re-estimation and adaptation,
would not beneﬁt from adaptation. Typically, a fast enrolment rate relative to the length of follow-
up will reduce the beneﬁts of using an adaptive design.
Figure 2. Four scenarios for the true dose-response relationship.
8 Statistical Methods in Medical Research 0(0)
 at The University of Edinburgh on October 7, 2015smm.sagepub.comDownloaded from 
Table 1 shows the range of design options and scenarios investigated in the design development
study. Four diﬀerent design options were included as outlined above (1. dose levels, 2. timing and
number of adaptations, 3. placebo allocation rate and 4. criterion for adaptation) and these were
considered under various scenarios covering assumptions in six critical areas (1. variance of MBL
measurements, 2. shape and 3. magnitude of the dose-response curve, 4. heteroscedastic error
variance, 5. moderation of treatment eﬀect by baseline MBL and 6. enrolment rate). With
reference to Table 1, one example of a simulated trial would have the design options (1.1.a),
(1.2.d), (1.3.c), (1.4.a) and scenario assumptions (2.1.b), (2.2.c), (2.3.b), (2.4.b), (2.5.b), (2.6.a), i.e.
a trial with all six active dose levels included, three adaptations (one after each of 10, 35 and 60
randomisations), a 2/7 placebo allocation rate and a play-the-winner adaptation rule investigated
under the scenario with MBL variance parameter of (22mL)2, a non-monotonic dose-response curve
with a treatment eﬀect of 16.4mL at the maximum eﬀective dose, heteroscedastic error variance,
treatment eﬀect proportionate to baseline MBL and a trial enrolment rate of 2 participants per
month.
5 Trial simulations
The performance of the many candidate designs was assessed under the various scenario options in a
substantial simulation exercise using a fractional factorial setup. We simulated all aspects of a trial
including screening, enrolment, randomisation, eﬀects of treatment, repeated interim analyses (at
pre-deﬁned points during enrolment as speciﬁed by the design), adaptation of subsequent
randomisation probabilities, and at the end of each trial, a ﬁnal analysis. Each such trial
simulation was repeated 200 times to ensure good precision in the performance characterisation
of the design under the particular scenario. Independent data were generated for each simulated trial
and design-scenario combination. Using a single control program we conducted the entire
simulation exercise from within SAS software version 9.3 (SAS Institute Inc., Cary, NC, United
States) which in turn invoked WinBUGS5 for Bayesian model estimation and empirical estimates of
posterior distributions. (The paper by Zhang et al. (2008)12 is an excellent resource on how to
control WinBUGS via a SAS program.)
At the core of the exercise was the simulation engine which generated the simulated trial data. We
aimed to mimic a real-life trial as closely as possible by simulating screening data at the eligibility
stage before enrolment. The DexFEM trial recruits participants who suﬀer from heavy menstrual
bleeding. For the purpose of the trial this has been deﬁned through the inclusion criteria as average
menstrual blood loss per period (collected over two menstrual cycles at screening and objectively
measured in a laboratory) in excess of 50mL.
The distribution of menstrual blood loss in the general population of women of reproductive age
is heavily skewed with most women’s MBL measuring below 50mL per period while some
experience very high levels of MBL. Informed by data from previous studies on MBL levels in
the general population13,14 and a more selected clinical study population,15 we approximated this
distribution using a log-normal distribution and modelled MBL levels in our simulation study on
this. To be included in our simulated trials, potential participants had to have an average MBL of at
least 50mL over the two screening measurements. Measurements taken from the same subject were
correlated and were modelled in a two-stage procedure:
MBL measurements from subject i at time point t were modelled as the sum of two random
variables
Yit ¼ Si þ Eit
Hansen et al. 9
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Si represented the underlying mean MBL level for subject i and was generated from the log-normal
distribution referred to above. The second term, Eit,N(0, e2) denoted the random deviation in the
observed MBL at time t from the subject’s underlying mean. We had evidence11 to support the
assumption that E was approximately normally distributed with e¼ 17.9mL. S and E were
assumed independent at ﬁrst. For each subject, we therefore simulated just one value for S but a
separate value for E for every new observation thereby inducing compound symmetry in the
covariance structure across repeated measurements. This approach had the added advantage that
regression to the mean was naturally imposed on the simulated data as part of the enrolment process.
After collecting two simulated measurements at screening, Y1 and Y2, eligible participants (i.e.
those with (Y1þY2)/2 50mL) were enrolled in the trial and allocated at random to receive either
Placebo with probability p or one of J 1 active doses with equal probability (1p)/(J 1).
Next, we added a treatment eﬀect, Dj(i), to participants’ underlying mean MBL level according to
the speciﬁed dose-response curve under the particular scenario. Having added a treatment eﬀect we
then simulated two further MBL measurements at follow up as Yit¼SiþDj(i)þEit, for t¼ {3,4}.
The process of screening and randomising eligible participants, adding treatment eﬀects and
sampling MBL outcomes at follow-up was then repeated until the ﬁrst interim analysis (when a
certain number of participants had been randomised in accordance with the adaptation schedule).
At this point we used a SAS macro16 to manipulate variables containing participants’ randomised
dose levels and MBL data from screening and follow-up into a format appropriate for parsing in
WinBUGS. The interim analysis was then executed with the relevant data ﬁles and model script
through a batch call in SAS.
An estimate of the dose-response curve was then computed in WinBUGS by ﬁtting the NDLM
(section 3) to the simulated interim data. Estimates of the treatment eﬀects at each dose level were
derived as the contrast j¼ j 1, for j¼ {2, . . . , J}.
Model parameter estimates were based on 10,000 simulated draws from the marginal posterior
distributions having discarded the ﬁrst 5000 iterations from the sampler (the burn-in). Convergence
of the MCMC sampler was monitored for selected design-scenario combinations by sampling from
two chains simultaneously using over-dispersed initial values and calculating the BGR diagnostic,17
coupled with visual inspection of the iteration histories.
Posterior estimates of the treatment eﬀects, and if appropriate, other relevant quantities necessary
for evaluating the utility function were then saved to text ﬁles and imported into SAS for processing.
Finally, allocation probabilities were updated according to the pre-speciﬁed adaptation rules and
applied to randomisations of new participants enrolling into the next stage of the trial. The process
was repeated until the next interim analysis, and so on, until all 100 participants were randomised.
At the end of the trial the ﬁnal model estimates were derived. A successful trial was deﬁned as one
where the posterior probability that  j> 0 was in excess of 97.5% for at least one of the active doses,
j2 {2, . . . , J}. The trial outcome (success or failure) was recorded along with other parameters used
for monitoring the simulations. These included the intermediate and ﬁnal model parameter
estimates, the number of participants randomised to each dose level overall and at each phase of
the trial, and the utility function evaluated at each dose level and phase of the trial. The process was
repeated 200 times for each trial design under the assumed scenario. The magnitude of the mean
treatment eﬀect estimates at each dose level was monitored to check for bias.
A fully factorial design would have entailed investigating nearly 10,000 unique design-scenario
combinations requiring almost 2,000,000 trial simulations. With each trial simulation taking up to
3.5min to complete on a standard speciﬁcation desktop PC, this number of simulations was not
feasible. Instead, we assessed a selected 142 relevant combinations of trial designs and scenarios
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amounting to 1.5% of a fully factorial design. The tasks and dialogue between the SAS Software and
WinBUGS are summarised in Figure 3. A detailed description of the simulation study including
plans for the design options and scenarios to be assessed was reviewed by the independent data
monitoring committee before the simulation was executed.
6 Methods for the analysis of simulation results
The changing pattern of randomised treatment allocations over the course of simulated trials was
summarised graphically to illustrate the extent to which the utility function being applied at each
adaptation achieved the desired modiﬁcations to the randomisation probabilities.
The quantitative design properties of interest were:
(1) Family-wise type I error rate Under the trial scenario where no Dexamethasone dose has any
beneﬁt over placebo (a ‘‘ﬂat’’ dose-response curve), the probability that the trial wrongly
concludes that at least one Dexamethasone dose is eﬃcacious.
(2) Trial power Here we use the statistical deﬁnition of disjunctive power:18 the probability that, in
the presence of a genuine Dexamethasone eﬀect, the trial correctly identiﬁes at least one
Dexamethasone dose as being eﬃcacious.
We used a normal linear model to analyse the results from the fractional factorial simulation
study. We modelled the overall eﬀect of each design option across a range of trial scenarios. Separate
models were ﬁtted for trial power (for simulated dose-response curves that included a true beneﬁt of
Dexamethasone) and type I error rate (for scenarios in which a ‘‘ﬂat’’ dose-response curve was
simulated). Important two-way interactions between design options and trial scenarios were
investigated within the normal linear model, for example to explore whether the impact on trial
power of increasing the number of adaptations diﬀered across a range of dose-response curve
shapes.
For each design option and trial scenario the mean change in statistical power relative to the
reference design option or trial scenario was estimated from the normal linear model alongside its
corresponding 95% conﬁdence interval.
7 Results from the simulation study
Figure 4 illustrates the evolving pattern of randomisations for one of the types of adaptation
evaluated: three in-trial adaptations after 20, 45 and 70 patients randomised. The randomisation
probabilities were adapted during the course of the trial using the ‘play-the-winner’ criterion
described in section 4.
Figure 5 conﬁrms that none of the design options simulated was associated with a signiﬁcant
change in the type I error rate estimated from the simulations. The overall type I error rate of 6.2%
(95% CI, 5.5% to 6.9%) was acceptable.
Figure 6 illustrates the association between three design options and statistical power. Adaptation
according to the precision of the estimated response at the ED95 (the minimum dose with near-
maximal eﬃcacy) showed a slight advantage over adaptation of allocation probabilities in
proportion to the current estimate of the probability that a dose is eﬃcacious in MBL reduction.
Statistical power was greater if only four rather than six active doses were studied, although the six
dose designs performed with acceptable power across scenarios. Having a higher proportion of
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Figure 3. The Simulation engine. White (grey) boxes indicate tasks performed in SAS (WinBUGS).
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participants randomised to placebo throughout the trial (2/7 versus 1/7) led to a substantial gain in
power.
Figure 7 describes the performance of various adaptation schedules in terms of statistical power.
Increasing the number of adaptations was beneﬁcial; with ﬁve adaptations, spreading those evenly
throughout recruitment after 16, 32, 50, 66 and 84 randomisations gave the highest point estimate of
statistical power.
Table 2 reports the relative impact of various design options and trial scenarios on statistical
power by listing the main eﬀects from the normal linear modelling. Recruitment rate and presence
of heteroscedasticity were not signiﬁcantly associated with trial power, although some variation in
power was observed for diﬀerent shapes of the dose-response curve. As expected, the magnitude of
treatment eﬀect and variability in the primary outcome were the dominant inﬂuences on power.
Increasing the proportion randomised to placebo, reducing the number of Dexamethasone doses
studied and various schedules of adaptive randomisation also provided a beneﬁt in terms of
statistical power. No important two-way interactions were identiﬁed in the normal linear
modelling.
Figure 4. Proportion of patients randomised to each of seven trial arms during the four phases of an adaptive trial
with three adaptations and fixed 28.6% allocation probability on placebo. Phase 1: before adaptation commences,
equal allocation probability across all active doses. Phase 2: after adaptation #1 based on MBL outcome data collected
on the first 20 patients. Phase 3: after adaptation #2 based on MBL outcome data collected on the first 45 patients.
Phase 4: after adaptation #3 based on MBL outcome data collected on the first 70 patients. The data presented are
the average proportions observed from 200 simulated trial runs. The most effective dose was between 1.0 and 1.2mg.
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8 Rationale for the adaptive design selected for DexFEM
We chose the following adaptive design for the DexFEM randomised, double-blind, placebo
controlled trial to identify the minimum Dexamethasone dose with near-maximal eﬃcacy.
(a) ﬁve adaptations;
(b) adaptations spaced evenly across the randomisation period, adapting after 16, 32, 50, 66, 84
patients have been randomised;
(c) use of a utility function to guide the adaptations based on the precision (the reciprocal of the
variance) of the estimated response at the ED95 (the minimum dose with near-maximal eﬃcacy)
after one further patient has been randomised;
(d) 6 dexamethasone doses (0.4, 0.8, 1.0, 1.2, 1.5, 1.8mg total daily dose);
(e) 28.6% (2/7) of patients allocated to placebo throughout.
Figure 5. (a) Estimated type I error rate and 95% CI under various scenarios. (b) Estimated type I error rate and
95% CI under various design options. Adaptation rule #1: adapts percentage randomised to each dose in proportion
to the current estimate of the probability that it is efficacious in MBL reduction. Adaptation rule #2: alters
randomisation according to the precision of the estimated response at the ED95 (the minimum dose with near-
maximal efficacy). (c) Estimated type I error rate and 95% CI, overall and under various design options.
14 Statistical Methods in Medical Research 0(0)
 at The University of Edinburgh on October 7, 2015smm.sagepub.comDownloaded from 
The simulation ﬁndings and other key considerations informed the design choice. Successive
increases in the number of adaptations led to corresponding increases in statistical power. While
there was no marked advantage of ﬁve adaptations over three, a 5-adaptation design with
adaptations evenly spaced throughout recruitment was considered feasible. As well as giving
fractionally the highest statistical power in simulations, the design is straightforward to
communicate to collaborators. We selected the utility function providing slightly greater
statistical power. The improved power of a 4-dose design over a 6-dose design is somewhat
counter-intuitive. This may be because in our simulated example, the subset of four doses by
chance included points on the dose response curve with greatest eﬃcacy. We nevertheless selected
the 6-dose design, because we aimed to study the largest possible number of doses while retaining
acceptable statistical power. Finally, we opted to randomise 2/7 of patients to placebo as this
provided much greater power than the alternative.
The statistical power of such a design estimated from the normal linear model is 93.8% (95%
conﬁdence interval 91.9% to 95.8%) for simulations on all shapes of dose response curve with a
mean beneﬁt over placebo of 16.4mL and a within patient MBL standard deviation of 17.9mL,
averaged across heteroscedasticity (present/absent) and interaction with baseline MBL (present/
absent), for a trial randomising four patients per month. For comparison, a conventional non-
adaptive design studying all six doses under similar scenarios would have 82.5% power.
Figure 5. Continued.
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9 Discussion
9.1 Summary of results
We identiﬁed a Bayesian adaptive dose-ﬁnding design which had high statistical power compared
with a standard parallel group design and which performed consistently regardless of trial
recruitment rate, shape of dose-response curve and deviations from the model assumptions.
A notable ﬁnding was the substantial gain in power from allocating a greater proportion of
participants to placebo: this is consistent with what would be expected from optimal design
theory and with what has been found in other parallel group designs evaluating multiple
treatments.19,6
Our simulation studies conﬁrmed that the use of an adaptive design conferred eﬃciency gains
over a conventional parallel group design. The statistical power of our chosen adaptive design is
substantially greater than that of a design which did not incorporate adaptations (93.6% versus
82.5%). This increase in eﬃciency is consistent with that found in the context of adaptive seamless
phase 2/3 designs20 where a similar level of improvement in statistical power equated to a 25–40%
saving in sample size.
Figure 5. Continued.
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The modelling of dose-response using the NDLM, coupled with the eﬃciency gains of our
adaptive design enables a greater number of doses to be studied; otherwise one is required to
select a subset of all available doses without prior knowledge of the dose response.21 This
necessary pre-selection of doses may lead to further loss of statistical power if, by chance, the
subset of doses selected does not include any of the more eﬃcacious doses.
9.2 Influences on design choice
The elicitation of expert clinician opinion described in section 4 indicated that from a mechanistic
perspective a monotone increasing dose response curve for Dexamethasone could not be guaranteed.
This required us to consider more sophisticated modelling of dose response, rather than simply
evaluating the highest feasible dose in a two-arm comparison versus placebo.
Figure 6. Main effects on statistical power of three design options. Estimates are averaged over all scenarios with a
‘genuine’ treatment effect. Adaptation rule #1: allocate in proportion to current probability that the treatment dose
affects at least some reduction in MBL. Adaptation rule #2: based on the precision (the reciprocal of the variance) of
the estimated response at the ED95 (the minimum dose with near-maximal efficacy) after one further patient has been
randomised (one-step-ahead approach). The vertical bars indicate 95% confidence intervals.
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The upper limit of six on the number of doses being evaluated was dictated by practical
considerations: it enables the doses under study to be reasonably closely spaced, while simplifying
the drug packaging process and minimising wastage of drug for doses whose allocation probabilities
are down-weighted following an adaptation.
Our simulations evaluated only two of the possible utility functions. We selected these on the
basis of ease of interpretation (the ‘‘play the winner’’ approach) and eﬃciency of adaptation
demonstrated in previous studies (quantifying the gain in information about the response at the
current estimate of the ED95).21,22
Although the fractional factorial simulation study design led to confounding of main eﬀects with
higher-order interaction terms, this was not a substantial constraint as we were still able to explore
two-way interactions between design options.
Given the volumetric nature of the MBL outcome, we might have expected there to be some
deviations from the normality assumptions in the NDLM. However, these did not prove
problematic, perhaps in part because our model studied the change from baseline and also
Figure 7. Main effect of the adaptation schedule. Estimates are averaged over all scenarios with a ‘genuine’
treatment effect. The labels along the horizontal axis indicate the number and timing of adaptations (e.g. ‘10;35;60’ is a
design with adaptations after 10, 35 and 60 randomisations). The vertical bars indicate 95% confidence intervals. The
reference category is ‘no adaptation’.
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adjusted for the baseline measurement. Had we identiﬁed evidence of non-normal errors, an
alternative option would have been to model the log-transformed MBL instead.
9.3 Practical aspects
Although the importance sampling approach assisted with the computational eﬃciency of the
simulations, nevertheless a period of 10 months was required to develop and conduct the
Table 2. Summary of main effects of design features from normal linear modelling of simulation outputs for all
scenarios containing a genuine dexamethasone effect.
Levels
Mean power change
versus reference P-valuea
Scenario Curve (1) Sine curve: steep 9% <0.0001
(2) Sine curve: slow 5% <0.0001
(3) Non-monotone Reference –
Variance (17.9mL)2 þ17% <0.0001
(22mL)2 þ8% <0.0001
(26mL)2 Reference –
Randomisation rate 2 pt/month -0.7% 0.24
4 pt/month Reference –
Maximum mean effect of
dexamethasone
16.4mL þ44% <0.0001
8.2mL Reference –
Mechanism No interaction þ3% 0.007
Treatment-BL interaction Reference –
Heteroscedasticity Absent þ0.4% 0.76
Present Reference –
Design option Timing of adaptations
(in terms of number of
patients randomised)
33 0% 0.86
50 þ4% 0.0010
66 þ6% 0.0058
10; 35; 60 þ6% 0.013
20; 45; 70 þ8% <0.0001
49; 66; 83 þ9% 0.0001
12; 24; 36; 48; 60 þ7% 0.0003
16; 32; 50; 66; 84 þ9% <0.0001
44; 55; 66; 77; 88 þ8% <0.0001
No adaptation Reference –
Utility function for
adaptations
Predicted increase in
precision of response
at ED95 after one future
randomisation
þ2% 0.033
Proportional to current
probability that dose
reduces MBL
Reference –
Doses Four active doses þ6% <0.0001
Six active doses Reference –
Placebo allocation rate 2/7 þ8% <0.0001
1/7 Reference –
aEach p-value is from the normal linear modelling of trial power and relates to the t-statistic comparing a given level to the reference
category.
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simulation study. Much of this time involved preparing the suite of statistical programs and
collaborating with experts in the therapeutic area to ensure that a credible set of design options
and assumptions were considered in the simulation study; the actual simulations required
approximately two months of processing time on a desktop PC. In part this was because a ‘‘belt
and braces’’ approach to the importance sampling was taken, with m¼ 100 observations being
simulated for each dose at each adaptation and 10,000 MCMC runs being performed on each.
This is consistent with other work9 which suggested that at the stage when only a low number of
patients have been randomised to a trial, larger numbers of simulated observations and MCMC runs
are preferable. In a larger trial than DexFEM, or in the later stages of DexFEM itself, a smaller
value of m and fewer MCMC runs should also be adequate.9
We implemented our simulations and adaptive design without the development of bespoke
software packages, as use of SAS and WinBUGS would maximise the generalisability of our
ﬁndings and the reuse of our programming code in other applications. The overall scope of our
simulations (200 trials per scenario; 150 scenarios; 10,000 MCMC runs following a 5000 iteration
burn-in for each model estimation step) was therefore inﬂuenced by this use of generic rather than
tailor-made software which will have had an impact on computational eﬃciency and simulation run
times. In addition to making use of readily available software, we linked programs in SAS and
WinBUGS to form a single integrated package through which to deliver the entire design
development study.
9.4 Technical considerations
The nature of the adaptive design means that not all of the placebo comparator patients are being
studied contemporaneously with those randomised to a Dexamethasone dose. This is particularly
notable for the doses given increased randomisation probabilities in the later stages of the adaptive
design. In order to account for this, the ﬁnal analysis of the trial should be stratiﬁed by adaptation
stage to ensure that within each stage a contemporaneous randomised comparison is being
considered.23 This accounts for so-called ‘‘cohort eﬀects’’ that would be induced by trends in
participant characteristics or protocol changes during the trial and ensures that the study retains
the perspective of concurrent control.24 This consideration applies to a broad range of adaptive
designs, including adaptive seamless designs, and is not restricted to the speciﬁc design implemented
in DexFEM.
The optimal spacing of adaptations will depend on the rate at which participants are randomised
to the trial25 as well as the length of follow up time between randomisation and assessment of
outcome. Our result showing that ﬁve adaptations equally spaced throughout recruitment had
marginally the greatest statistical power is consistent with the ﬁndings in adaptive seamless phase
II/III designs20 which gave greatest adaptive seamless design eﬃciency when equal numbers of
patients were included in phase II and phase III, rather than in the ratio 1:2 or 1:3. As our MBL
primary outcome measure is available soon after treatment relative to the length of the period of
recruitment to the trial, there was no requirement to seek an intermediate outcome on which to base
adaptations, as recommended in situations where the primary outcome is measured following a
lengthy follow-up period.26 An optimal group sequential testing framework is available in such a
scenario.27
Our proposed design adapts on eﬃcacy only, which is justiﬁable as Dexamethasone is already
licenced and its safety proﬁle well-established for much higher acute doses than the repeated doses
for longer-term use that mimic physiological glucocorticoid secretion which are studied in DexFEM.
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In other situations, there would be the scope to adapt simultaneously on both eﬃcacy and toxicity
data, for example using the ‘‘trinary’’ ordinal outcome approach28 which combines these outcomes
as 0: no eﬃcacy and no toxicity, 1: eﬃcacy and no toxicity and 2: toxicity. Thall and Cook 29 develop
these approaches further by considering a bivariate binary outcome which incorporates both eﬃcacy
and safety information.
10 Conclusion
This simulation study has enabled us to develop a Bayesian response-adaptive design which
maximises what can be learned about the Dexamethasone dose-response relationship from this
clinical trial in heavy menstrual bleeding, substantially gaining eﬃciency over a standard parallel
group design. The ﬂexible approach we have reported identiﬁes a design which performs robustly
across a range of potential trial scenarios, and which remains feasible to deliver as it incorporates a
manageable number of adaptations and is based on widely available statistical software. In a
separate paper we will report on the technical aspects of using simulations to inform the
development of an adaptive design, providing tips on how best to implement this using SAS and
WinBUGS and including all of our statistical programming code.
Acknowledgements
We thank the DexFEM research team (co-investigators John Iredale, Philippa Saunders, Stephen Hillier &
Scott Semple; research nurses Catherine Murray & Sharon McPherson; trial coordinator Anne Douglas;
clinical researcher Mayank Madhra; laboratory support Moira Nicol and Alison Murray; secretaries Sheila
Milne & Anne Houghton), NHS Pharmacy (Hazel Milligan), ACCORD (Ray French, Marise Bucukoglu,
Bernadette Gallagher), ECTU (Allan Walker, Gary Milne, Gina Cranswick, Sam Thomas), NHS Lothian
(Gerry Beattie), Chalmers Clinic (Ailsa Gebbie, Sharon Cameron), SPCRN (Ellen Drost), UoE TTO (Giles
Dudley), Trial Steering Committee (Mary Ann Lumsden, Siladitya Bhattacharya, Dharani Hapangama), Data
Monitoring Committee (Justin Clark, Ertan Saridogan, Rebecca Reynolds, Adrian Mander) and Tayside
Pharmaceuticals (Baxter Millar).
Funding
The DexFEM programme of research is funded by the Medical Research Council Developmental Clinical
Studies scheme [Grant No. MR/J003611/1]; CJW and RAP were supported in this work by NHS Lothian
via the Edinburgh Health Services Research Unit; and BRW is supported by the British Heart Foundation.
Declaration of conflicting interests
The author(s) declared no potential conﬂicts of interest with respect to the research, authorship, and/or
publication of this article.
References
1. Smith MK, Jones I, Morris MF, et al. Implementation of a
Bayesian adaptive design in a proof of concept study.
Pharm Stat 2006; 5: 39–50.
2. Rae M, Mohamad A, Price D, et al. Cortisol inactivation
by 11beta-hydroxysteroid dehydrogenase-2 may enhance
endometrial angiogenesis via reduced thrombospondin-1
in heavy menstruation. J Clin Endocrinol Metab 2009; 94:
1443–1450.
3. Warner P, Weir CJ, Hansen CH, et al. Low dose
dexamethasone as a treatment for women with heavy
Hansen et al. 21
 at The University of Edinburgh on October 7, 2015smm.sagepub.comDownloaded from 
menstrual bleeding: protocol for response-adaptive
randomised placebo-controlled dose-finding parallel group
trial (DexFEM). BMJ Open 2015; 5: e006837.
4. West MJ and Harrison PJ. Bayesian forecasting and
dynamic models. New York: Springer-Verlag, 1997.
5. Spiegelhalter DJ, Thomas A, Best NG, et al. WinBUGS
version 1.4 user manual. MRC Biostatistics Unit,
Cambridge, www.mrc-bsu.cam.ac.uk/bugs (2003, accessed
2 September 2015).
6. Sydes MR, Parmar MKB, James ND, et al. Issues in
applying multi-arm multi-stage methodology to a clinical
trial in prostate cancer: the MRC STAMPEDE trial. Trials
2009; 10: 39.
7. Bookman MA, Brady MF, McGuire WP, et al. Evaluation
of new platinum-based treatment regimens in advanced-
stage ovarian cancer: a phase III trial of the Gynecologic
Cancer InterGroup. J Clin Oncol 2009; 27: 1419–1425.
8. Gelfand AE. Model determination using sampling-based
methods. In: Gilks WR, Richardson S and Spiegelhalter
DJ (eds) Markov Chain Monte Carlo in Practice. London:
Chapman and Hall, 1996, pp.145–161.
9. Weir CJ, Spiegelhalter DJ and Grieve AP. Flexible design
and efficient implementation of adaptive dose-finding
studies. J Biopharm Stat 2007; 17: 1033–1050.
10. Oakley JE and O’Hagan A. SHELF: The Sheffield
Elicitation Framework (Version 2.0). School of
Mathematics and Statistics, University of
Sheffield,www.tonyohagan.co.uk/shelf (accessed 2 March
2015).
11. Fraser IS, Warner P and Marantos PA. Estimating
menstrual blood loss in women with normal and excessive
menstrual fluid volume. Obstet Gynaecol 2001; 98:
806–814.
12. Zhang Z, McArdle JJ, Wang L, et al. A SAS interface for
Bayesian analysis with WinBUGS. Struct Equ Model
Multidiscip J 2008; 15: 705–728.
13. Hallberg L, Hogdahl AM, Nilsson L, et al. Menstrual
blood loss – a population study. Variation at different ages
and attempts to define normality. Acta Obstet Gynecol
Scand 1966; 45: 320–351.
14. Cole SK, Thomson AM and Billewicz WZ. Sources of
variation in menstrual blood loss. J Obstet Gynecol Br
Commonw 1971; 78: 933–939.
15. Warner P, Critchley HOD, Lumsden MA, et al.
Menorrhagia I: Measured blood loss, clinical features and
outcome in women with heavy periods: a survey with
follow-up. AJOG 2004; 190: 1216–1223.
16. Sparapani R. Some SAS macros for BUGS/WinBUGS
data. ISBA Bull 2004; 11: 8–10.
17. Brooks SP and Gelman A. Alternative methods for
monitoring convergence of iterative simulations. J Comput
Graph Stat 1998; 17: 434–455.
18. Senn S and Bretz F. Power and sample size when multiple
endpoints are considered. Pharm Stat 2007; 6: 161–170.
19. Parmar MKB, Barthel FM-S, Sydes M, et al. Speeding up
the evaluation of new agents in cancer. J Natl Cancer Inst
2008; 100: 1204–1214.
20. Chataway J, Nicholas R, Todd S, et al. A novel adaptive
design strategy increases the efficiency of clinical trials in
secondary progressive multiple sclerosis. Mult Scler 2011;
17: 81–88.
21. Berry DA, Mueller P, Grieve AP, et al. Adaptive Bayesian
designs for dose-ranging drug trials. In: Gatsonis C, Carlin
B and Carriquiry A (eds) Case Studies in Bayesian
Statistics. New York: Springer-Verlag, 2001, pp.99–181.
22. Krams M, Lees KR, Hacke W, et al. Acute stroke therapy
by inhibition of neutrophils (ASTIN): an adaptive dose-
response study of UK-279,276 in acute ischemic stroke.
Stroke 2003; 34: 2543–2548.
23. Bailey R. Designs for dose-escalation trials with
quantitative responses. Stat Med 2009; 28: 3721–3728.
24. Senn S. Commentary on ‘Designs for dose-escalation trials
with quantitative responses’. Stat Med 2009; 28:
3754–3758.
25. Gallo P, Chuang-Stein C, Dragalin V, et al. Adaptive
designs in clinical drug development—an Executive
Summary of the PhRMA Working Group. J Biopharm
Stat 2006; 16: 275–283.
26. Kunz CU, Friede T, Parsons N, et al. Data-driven
treatment selection for seamless phase II/III trials
incorporating early-outcome data. Pharm Stat 2014; 13:
238–246.
27. Hampson LV and Jennison C. Group sequential tests for
delayed responses. J R Stat Soc Ser B 2013; 75: 3–54.
28. Thall PF and Russell KE. A strategy for dose-finding and
safety monitoring based on efficacy and adverse outcomes
in phase I/II clinical trials. Biometrics 1998; 54: 251–264.
29. Thall PF and Cook JD. Dose-finding based on efficacy-
toxicity trade-offs. Biometrics 2004; 60: 684–693.
Appendix 1
There is evidence in Fraser et al.11 that MBL scores are subject to heteroscedastic error variance:
women who experience greater average MBL tend to exhibit more variability in their observed MBL
measurements. It was important to investigate the eﬀects of such a mechanism and we therefore
included scenarios in our work-up study which simulated separate error variances as a function of
Si, the underlying mean MBL for participant i. Thus, individual error variances were generated as
Var Eið Þ ¼ Aþ B exp Si=100ð Þ  Cð Þ
where Ei is the random deviation in the observed MBL from Si, C is a mean centring constant and A
is the variance under scenarios with homoscedastic error variance (i.e. when B¼ 0). For scenarios
allowing diﬀerent error variances for each participant we used a value (198) for B which was
estimated in a separate model of empirical data from the Fraser study.11 Heteroscedastic error
variances were simulated for each of the relevant three values of A: (17.9)2, (22.0)2 and (26.0)2.
(For completeness, the mean centring constant used was C¼ 2.837.)
22 Statistical Methods in Medical Research 0(0)
 at The University of Edinburgh on October 7, 2015smm.sagepub.comDownloaded from 
For near-zero values of S this function for Var(E) yielded unrealistically small or even negative
values. The function was therefore restricted to not produce values below Var(E)¼ 6. This is
consistent with the variance observed amongst the patients in the Fraser study11 with the lowest
observed mean MBL. At the other end of the scale, for values of S near 400mL the variance
function yielded extremely large values. Consequently the function was also restricted to not
produce values above Var(E)¼ (70.7)2¼ 5000, which was about twice the largest observed
variance in the Fraser study11.
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